Tools
Stock profile

Schrodinger, Inc. (SDGR)

SDGR · Latest close $27.20 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$27.20
As of Nov 18, 2026
Tracked funds holding
2 of 149
2026 Q2 13F filings
Opened / added
0 / 1
vs previous quarter
Trimmed / exited
0
vs previous quarter

Schrodinger, Inc. (SDGR) is held by 2 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund adding versus the previous quarter. Insiders were net sellers over the last 90 days ($0 bought vs $2.8M sold). Latest close $27.20 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Nov 11, 2026 · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Insiders · 90d
net $-2.8M
Fundamentals
Revenue · FY2025
Red flags
screens flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Fails to deliver · Insider trading · 5% holders · Planned sales · Politician trading · Committee jurisdiction · Government relations · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

Rubric Capital Management · Bill & Melinda Gates Foundation Trust — 2 tracked funds hold SDGR. See all holders.

Insider and Congress activity

Insiders bought on the open market (0 purchases, $0) vs 8 sales ($2.8M). Insider trading

Often held alongside

Merck & Co., Inc. (MRK) · ELI LILLY & Co (LLY) · PFIZER INC (PFE) · AbbVie Inc. (ABBV) · BRISTOL MYERS SQUIBB CO (BMY) — stocks the same funds also hold. See all related stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
Rubric Capital Management0.95%6,400,000ADDED (+6.7%) Q3 filed Nov 16
Bill & Melinda Gates Foundation Trust0.33%6,981,664HELD Q3 filed Nov 16

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: +56.6% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

33.3910.182024-11-192026-11-18

Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

All institutions · Form 13F

Institutions holding233 of 8,857 filers
Long-only filers among them231
Change vs 2026 Q1+11 net · 230 entered · 219 exited
Shares reported, all filers64,708,239
Reported value, all filers$1.1B

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNasdaq
IndustryPharmaceutical Preparations (SIC 2834)
Revenue · FY2025$255.9M
Net income · FY2025$-103.3M
Total assets · FY2025$726.2M
Shares outstanding73,443,298
Market cap (at latest close)$2.0B

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Dec 31, 2025.

Short interest

Shares short · Oct 15, 202610,402,258
Share of shares outstanding14.16%
Days to cover3.35

Shares short at recent settlements — Jul 31, 2026: 11.0M · Aug 14, 2026: 11.4M · Aug 31, 2026: 11.1M · Sep 15, 2026: 11.2M · Sep 30, 2026: 10.1M · Oct 15, 2026: 10.4M.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Dec 31, 2025.

Fails to deliver

Shares failed to deliver · Oct 14, 20260
Share of shares outstanding0.00%
Fails as a share of short interest · Oct 15, 20260.0%

Fails to deliver at recent settlements — Jul 31, 2026: 56 · Aug 14, 2026: 0 · Aug 31, 2026: 11K · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 0.

Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Dec 31, 2025.

Insider trading · Form 4

0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 8 sales by 3 insiders ($2.8M).

Source: SEC Form 4 filings. Open-market transactions only.

Recent open-market trades

DateInsiderRoleBuy / SellSharesPriceValueSource
Nov 11, 2026Abel Robert LorneSee RemarksSell21,927$34.00$745.5KSEC filing
Nov 11, 2026Abel Robert LorneSee RemarksSell1,678$34.00$57.1KSEC filing
Nov 9, 2026Tran YvonneEVP, CLO & CPOSell400$29.97$12.0KSEC filing
Nov 9, 2026Tran YvonneEVP, CLO & CPOSell2,100$31.45$66.1KSEC filing
Nov 9, 2026Tran YvonneEVP, CLO & CPOSell7,901$32.64$257.9KSEC filing
Nov 9, 2026Tran YvonneEVP, CLO & CPOSell21,599$33.11$715.2KSEC filing
Sep 17, 2026Akinsanya KarenSee RemarksSell10,000$28.00$280.0KSEC filing
Sep 17, 2026Akinsanya KarenSee RemarksSell21,599$30.00$648.0KSEC filing

Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.

Planned sales · Form 144

FiledSellerRoleShares to sellMarket valueApprox. sale dateSource
Sep 17, 2026KAREN OLUFUNMILYO AKINSANYA-AKIWUMIOfficer31,599$756.2KSep 17, 2026SEC filing
Jul 16, 2026Jain RachitOfficer875$13.6KJul 16, 2026SEC filing
Jul 1, 2026Aklian Mannix VartanOfficer1,136$18.9KJul 1, 2026SEC filing
May 1, 2026Herman JennyOfficer1,957$24.0KMay 1, 2026SEC filing
Apr 16, 2026Jain RachitOfficer844$10.8KApr 16, 2026SEC filing
Apr 16, 2026RAMY SAMIR FARIDDirector, Officer86,000$1.1MApr 16, 2026SEC filing
Mar 6, 2026Herman JennyOfficer608$7.8KMar 6, 2026SEC filing
Mar 5, 2026Lorton Kenneth PatrickOfficer1,222$15.8KMar 5, 2026SEC filing
Mar 5, 2026Tran YvonneOfficer1,094$14.1KMar 5, 2026SEC filing
Mar 5, 2026Herman JennyOfficer775$10.0KMar 5, 2026SEC filing

A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
May 15, 2026Rubric Capital Management LPSC 13G/A6,000,0009.3%Mar 31, 2026SEC filing
Apr 30, 2026Sumitomo Mitsui Trust Group, Inc.SC 13G/A3,190,8374.9%Mar 31, 2026SEC filing
Apr 29, 2026Vanguard Portfolio ManagementSC 13G3,911,0876.0%Mar 31, 2026SEC filing
Mar 27, 2026The Vanguard GroupSC 13G/A00.0%Mar 13, 2026SEC filing
Feb 13, 2026Rubric Capital Management LPSC 13G/A4,171,4986.5%Dec 31, 2025SEC filing
Oct 27, 2025Sumitomo Mitsui Trust Group, Inc.SC 13G/A4,554,5697.1%Sep 30, 2025SEC filing
Jul 18, 2025BlackRock, Inc.SC 13G/A8,164,48412.7%Jun 30, 2025SEC filing
Feb 13, 2025Rubric Capital Management LPSC 13G/A5,000,0007.8%Dec 31, 2024SEC filing
Feb 4, 2025Sumitomo Mitsui Trust Group, Inc.SC 13G3,510,5185.5%Dec 31, 2024SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).

Committee jurisdiction

Industry: Pharmaceutical Preparations (SIC 2834). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.

None of the members who traded this stock in the current window sit on these committees.

Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.

Government relations

Lobbying: no Lobbying Disclosure Act filings matched for this ticker (1999–2026).

Federal contracts: $2.0M in obligated amounts, fiscal years 2021–2026.

Fiscal yearObligated amount
FY2021$382.4K
FY2022$885.6K
FY2023$669.2K
FY2024$64.5K
FY2025$0
FY2026$-4.0K

Largest awards collected

Award IDAgencyAmountStart
75N95022P00669Department of Health and Human Services$247.5KSep 23, 2022
75N91021P00674Department of Health and Human Services$18.1KJul 28, 2021
15DDHQ24P00000074Department of Justice$540Nov 27, 2023

Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.

Screens & lenses

Chart Signals

· Monthly Uptrend — Price above its 12-month moving average

· Top Relative Strength — Top 20% of the universe by 6-month return

Red Flags

· Distress Risk (Altman Z″) — Altman Z″-Score below 1.10

Key figures

· Distress Risk (Altman Z″) — Z″-Score: -0.33 · Working capital / assets: 0.45 · Retained earnings / assets: -0.87 · EBIT / assets: -0.23 · Equity / liabilities: 1.01

Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.

Also held by the tracked funds that hold SDGR — ranked by lift, the co-holding pattern described in Methodology: Merck & Co., Inc. (MRK) · ELI LILLY & Co (LLY) · PFIZER INC (PFE) · AbbVie Inc. (ABBV) · BRISTOL MYERS SQUIBB CO (BMY) · ASTRAZENECA PLC (AZN) · ABBOTT LABORATORIES (ABT) · NOVARTIS AG (NVS).

8 of the 8 are same-industry (SIC) fillers: fewer than 4 stocks met the lift rule for this stock.

Recent 8-K filings

FiledItemsSource
Nov 4, 20262.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and ExhibitsSEC filing
Aug 5, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing
Jun 29, 20267.01 Regulation FD DisclosureSEC filing

Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.

Related

Merck & Co., Inc. (MRK) · Track Record: how the signals scored · Practice timing on SDGR

One email a week: the week’s new filings and research. Subscribe free

← SD  ·  SDHC →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.